Furthermore, the elevated phosphorylation of Akt and subsequent up-regulation of survivin expression were suggested to promote the resistance of breast cancer to lapatinib and of colorectal cancer to cetuximab [14, 21]. Here, BIRC5 is linked to breast carcinoma.